Physician profile
Mark A Blakeslee
NPI 1154340461
$1,669.59
in general payments reported to CMS, 2019-2025
19 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $186 · 2021: $78.70 · 2022: $42.58 · 2023: $69.29 · 2024: $52.93 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392 · Travel and Lodging: $14.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.40 |
| Travel and Lodging | $14.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $220.07 | 2025 | Percept Pc Brainsense |
| Abbvie INC. | $210.82 | 2022-2025 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $196.21 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $160.24 | 2019-2020 | |
| Genzyme Corporation | $159.08 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $144.60 | 2019-2020 | |
| Ucb, INC. | $117.19 | 2019 | |
| Biogen, INC. | $83.12 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $68.35 | 2019 | |
| Adamas Pharmaceuticals, INC. | $51.31 | 2019 | |
| Amgen INC. | $50.76 | 2019-2022 | |
| Acorda Therapeutics, INC | $37.75 | 2019 | |
| Allergan, INC. | $36.34 | 2021 | |
| Mdd US Operations, LLC | $33.85 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $28.45 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.56 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2019 | |
| Lilly USA, LLC | $13.91 | 2021 | |
| Pfizer INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blakeslee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.